Key Insights

Highlights

Success Rate

94% trial completion (above average)

Published Results

37 trials with published results (15%)

Research Maturity

172 completed trials (68% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.3%

11 terminated out of 253 trials

Success Rate

94.0%

+7.5% vs benchmark

Late-Stage Pipeline

19%

49 trials in Phase 3/4

Results Transparency

22%

37 of 172 completed with results

Key Signals

37 with results94% success11 terminated

Data Visualizations

Phase Distribution

170Total
Not Applicable (37)
Early P 1 (1)
P 1 (70)
P 2 (13)
P 3 (31)
P 4 (18)

Trial Status

Completed172
Unknown30
Recruiting22
Terminated11
Not Yet Recruiting7
Active Not Recruiting5

Trial Success Rate

94.0%

Benchmark: 86.5%

Based on 172 completed trials

Clinical Trials (253)

Showing 20 of 20 trials
NCT00353158Phase 1Completed

A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity

NCT02687906Phase 1Active Not RecruitingPrimary

Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

NCT07612163RecruitingPrimary

Clinical Efficacy and Population Pharmacokinetics of β-lactams in Cirrhotic Patients

NCT07607470Not Yet RecruitingPrimary

Large Algorithm Setting and Validation Study

NCT02655302Not ApplicableTerminated

Study of the Involvement of IL-17 / IL-22 Pathway in Bacterial Exacerbations of COPD

NCT05336851Recruiting

Emergency PWAS in Respiratory Infectious Disease

NCT07062445Recruiting

Prospective Clinical Registry of Acute Treatment and Long-term Assessment of Children Meningitis

NCT06592586Phase 2Active Not Recruiting

A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women

NCT07367295Not Yet RecruitingPrimary

Prospective Clinical Study, Using a Medical Device (RepHegyn) as an Adjuvant in the Treatment of Fungal (Candidiasis) and Bacterial Infections

NCT05645107Phase 3Recruiting

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

NCT07470541Not ApplicableNot Yet Recruiting

Viromes in Infants Presenting With a Septic Syndrome

NCT05217537Phase 1CompletedPrimary

Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

NCT07017777Phase 3Recruiting

A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

NCT06704048Not ApplicableRecruiting

Healthrelated Quality of Life and Experiences of a Heart Rehabilitation Programme After Care for Infective Endocarditis.

NCT05914467Phase 4Active Not RecruitingPrimary

TDM-optimized Teicoplanin Dosing Versus Standard of Care

NCT04263792Phase 1RecruitingPrimary

[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

NCT03424525Phase 1CompletedPrimary

11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

NCT06079775Phase 1CompletedPrimary

P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants

NCT05611905Completed

Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid

NCT05722184CompletedPrimary

Diagnostic Evaluation Study of the BactInsight Blood Culture System in West-Africa

Scroll to load more

Research Network

Activity Timeline